Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Paclitaxel + Tegafur-gimeracil-oteracil Potassium |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Paclitaxel | Taxol | 7-Epipaclitaxel | Antimicrotubule Agent 12 BCL2 Family Inhibitor 6 | Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary). |
Tegafur-gimeracil-oteracil Potassium | TS-1|BMS-247616 | Chemotherapy - Antimetabolite 12 | Tegafur-gimeracil-oteracil Potassium (TS-1) is composed of tegafur, gimestat and otastat potassium, of which the ultimate active ingredient is 5-FU (PMID: 12066214, PMID: 32233637). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | gastric adenocarcinoma | not applicable | Paclitaxel + Tegafur-gimeracil-oteracil Potassium | Phase III | Actionable | In a Phase III trial, combining intraperitoneal Taxol (paclitaxel) with TS-1 (tegafur-gimeracil-oteracil potassium) and Taxol did not show statistical improvement of overall survival, but did demonstrated clinical efficacy compared to TS-1 and cisplatin combination in gastric adenocarcinoma patients with peritoneal metastasis (J Clin Oncol 34, 2016 (suppl; abstr 4014)). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|